Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for severe COVID-19
RBR-876qb5Phase 2Recruiting
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in coronavirus disease 2019 (COVID-19), sponsored by Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto. Started May 2020; status: recruiting.
02
Drugs
eculizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-876qb5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-876qb5.